This post is about Seracare’s new direction for Precision Medicine (in particular Precision Oncology), and the launch of a new product the Seraseq Solid Tumor Mutation Mix-I (AF20). But I’ll start first with a story from my days at Illumina.
It was ten years ago this week that I last launched a product. It was the Illumina Infinium Human-1 Genotyping BeadChip, and it took months of hard work, many core-team meetings, plenty of long days and many hallway discussions about the finest details of the product. Long days and many meetings go together: how can you get the things you commit to in a meeting ever done if you go to many meetings?
And in case anyone is wondering, yes that is the job of a Product Manager – you get to work hard and work closely with a team from across different areas of the company (research, manufacturing, quality, support, and engineering) and you get to experience many ups-and-downs, and learn things about yourself and others through this experience that you carry with you. These may be hard days, but they are good ones.
